SURGICAL CONTROL OF THE HYPERLIPIDEMIAS

高脂血症的手术控制

• 批准号: 3334912
• 负责人: HENRY BUCHWALD
• 金额: $ 158.67万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-09 至 1992-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3334912
• 关键词: angiography; atherosclerosis; automated medical record system; biomedical facility; blood chemistry; cardiovascular disorder epidemiology; cardiovascular disorder prevention; cardiovascular stress test; cholesterol; electrocardiography; high density lipoproteins; human morbidity; human mortality; human subject; human therapy evaluation; hyperlipidemia; longitudinal human study; low density lipoprotein; myocardial infarction; stomach /intestine bypass; triglycerides; ultrasound blood flow measurement; vector cardiography; very low density lipoprotein

The Program on Surgical Control of the Hyperlipidemias (POSCH) is a secondary (post a single myocardial infarction, unifactorial (hypertension, diabetes, and other major risk factors excluded) atherosclerosis-lipid intervention trial. The core facilities of POSCH (Central Lipid Laboratory, Central Electrocardiography Laboratory, Central Arteriography/ Radiology Laboratory, and the Office of Programs Administration) are located at the University of Minnesota; the four clinical centers of POSCH are at the University of Minnesota, University of Arkansas, University of Southern California, and the Lankenau Research Center, Philadelphia. The mode of intervention for POSCH is the partial ileal bypass operation. POSCH data have documented that this procedure causes a 25% reduction in total plasma cholesterol, a 40% LDL-cholesterol lowering, an 8% increase in the HDL-cholesterol, and an 80% increase in the HDL/LDL ratio. In addition to clinical endpoints, this trial provides sequential analyses of coronary arteriograms for at least five years after randomization for each participant. Recruitment and screening terminated in 1982-1983, and randomization terminated July 19, 1983 with 838 participating subjects. POSCH is currently in its follow-up phase. This application is for the completion of follow-up, termination of the trial, and analysis and publication of data. The results of this trial will answer the questiion of whether total plasma cholesterol reduction, or more precisely the lowering of the LDL-cholesterol and the raising of the HDL-cholesterol fractions, will affect the atherosclerosis process after a myocardial infarction.

高脂血症手术控制计划 (POSCH) 是一项 继发性（单次心肌梗塞后、单因素（高血压、 糖尿病，排除其他主要危险因素）动脉粥样硬化-脂质 干预试验。 POSCH（Central Lipid）的核心设施 实验室、中心心电图实验室、中心动脉造影/ 放射学实验室和项目管理办公室） 位于明尼苏达大学； POSCH的四个临床中心 分别就读于明尼苏达大学、阿肯色大学、 南加州和费城兰克瑙研究中心。 这 POSCH的干预方式是部分回肠旁路手术。 POSCH 数据证明，该程序可导致 25% 的减少 血浆总胆固醇，低密度脂蛋白胆固醇降低 40%，胆固醇水平增加 8% HDL-胆固醇，HDL/LDL 比率增加 80%。 此外 对于临床终点，该试验提供了冠状动脉的序贯分析 每项随机化后至少五年进行动脉造影 参与者。 招募和筛选于 1982-1983 年终止，并且 随机分组于 1983 年 7 月 19 日结束，共有 838 名受试者参加。 POSCH目前正处于后续阶段。 此应用程序适用于 完成随访、终止试验、分析和 数据的发布。 这次试验的结果将回答这个问题 血浆总胆固醇是否降低，或者更准确地说 降低 LDL 胆固醇和升高 HDL 胆固醇 分数，会影响心肌梗死后的动脉粥样硬化过程 梗塞。